First-line approval of HYRNUO ® (sevabertinib) for patients with advanced HER2-mutated non-small cell lung cancer (NSCLC) follows U.S. Food and Drug Administration (FDA) Priority ...

Warming — which has been documented throughout the Great Lakes region — compresses the narrow band of habitat where walleye ...

Sometimes a boundary is just a line in the road. But sometimes it’s a gate from one world to another. Driving due south from ...

By Jeff Oloizia for Madison Magazine. Broadcast version by Judith Ruiz-Branch for Wisconsin News Connection reporting for the ...

This is the tragedy of Murree—a tragedy written in the blood of a million children, a tragedy that the world cannot afford to ignore ...

This is a valuable study that contributes to our understanding of transcriptomic responses in microglia to HIV infection in the human brain. The evidence provided remains incomplete, and further ...

Enhertu Demonstrated a Median 14.3 Month Progression-Free Survival as First-Line Therapy in Patients with HER2 Mutant ...

Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically ...

Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab demonstrated a statistically significant and highly ...

In 1971, Canadian primatologist Biruté Galdikas embarked on an extensive journey into orangutan research in Indonesian Borneo ...

A randomized phase III trial found that scheduled brain-MRI surveillance without preventive cranial radiation improved ...

11-07-2026 09:09 A selection of the stories that caught our eye over the last seven days in Argentina.